NCT02012231View on ClinicalTrials.gov

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

June 30, 2015

Conditions
MelanomaThyroid CancerColorectal CancerNon-small Cell Lung CancerCholangiocarcinomaHistiocytosisHairy Cell Leukemia
Interventions
DRUG

PLX8394

PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.

Trial Locations (3)

84112

Huntsman Cancer Institute, Salt Lake City

85258

Scottsdale Healthcare, Scottsdale

99218

Evergreen Hematology & Oncology, Spokane

Sponsors
All Listed Sponsors
lead

Fore Biotherapeutics

INDUSTRY